Nerviano, Trovagene deal

Nerviano granted Trovagene exclusive, worldwide rights to develop and commercialize PCM-075 (NMS-1286937). The candidate is the first cancer therapeutic in Trovagene's pipeline. Nerviano will receive $2 million up front and is eligible for development milestones and regulatory milestones as well as royalties. Milestones can be triggered upon the start of a Phase III trial of PCM-075, an NDA submission for PCM-075 and the candidate's launch. The polo-like kinase 1 (PLK1; STPK13) selective inhibitor has completed a Phase I trial in advanced metastatic cancer patients. This year, Trovagene plans to start a Phase II trial of the oral small molecule to treat acute myelogenous leukemia (AML). ...